Mar182019 Anavex Life Sciences Announces First Patient Dosed in Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Rett Syndrome in the U.S. March 18, 2019
Mar112019 Anavex Life Sciences Reaches 50% Enrollment Threshold in ANAVEX®2-73 Parkinson’s Disease Dementia (PDD) Phase 2 Study Ahead of Schedule March 11, 2019
Mar62019 Anavex Life Sciences to Present at the Cowen 39th Annual Health Care Conference 2019 March 6, 2019
Mar42019 Anavex Life Sciences Reports Publication of New Data that Show ANAVEX®2-73 Induces Cellular Recycling Process Linked to the Prevention and Treatment of Age-Associated Diseases March 4, 2019
Feb72019 Anavex Life Sciences Reports Fiscal 2019 First Quarter Financial Results And Provides Clinical Study Updates February 7, 2019
Jan312019 Anavex Life Sciences to Announce Fiscal 2019 First Quarter Financial Results on Thursday, February 7th, 2019 January 31, 2019
Jan22019 Anavex Life Sciences Announces the Appointment of Walter E Kaufmann, MD as Chief Medical Officer January 2, 2019
Dec122018 Anavex Life Sciences Reports Fiscal Year 2018 Financial Results And Provides Clinical Study Update December 12, 2018
Dec102018 Anavex Life Sciences to Announce 2018 Fiscal Year End Financial Results on Wednesday, December 12, 2018 December 10, 2018
Nov82018 Anavex Life Sciences Strengthens its Scientific Advisory Board with Distinguished Researcher for Clinical Treatment of Parkinson’s Disease Dementia (PDD) November 8, 2018
